Literature DB >> 29203712

Heat shock protein 90: its inhibition and function.

Abbey D Zuehlke1, Michael A Moses1, Len Neckers2.   

Abstract

The molecular chaperone heat shock protein 90 (Hsp90) facilitates metastable protein maturation, stabilization of aggregation-prone proteins, quality control of misfolded proteins and assists in keeping proteins in activation-competent conformations. Proteins that rely on Hsp90 for function are delivered to Hsp90 utilizing a co-chaperone-assisted cycle. Co-chaperones play a role in client transfer to Hsp90, Hsp90 ATPase regulation and stabilization of various Hsp90 conformational states. Many of the proteins chaperoned by Hsp90 (Hsp90 clients) are essential for the progression of various diseases, including cancer, Alzheimer's disease and other neurodegenerative diseases, as well as viral and bacterial infections. Given the importance of these clients in different diseases and their dynamic interplay with the chaperone machinery, it has been suggested that targeting Hsp90 and its respective co-chaperones may be an effective method for combating a large range of illnesses.This article is part of the theme issue 'Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective'.
© 2017 The Author(s).

Entities:  

Keywords:  Heat Shock Protein 90; drug development; molecular chaperones

Mesh:

Substances:

Year:  2018        PMID: 29203712      PMCID: PMC5717527          DOI: 10.1098/rstb.2016.0527

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  54 in total

1.  A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice.

Authors:  Chieh-Fang Cheng; Divya Sahu; Fred Tsen; Zhengwei Zhao; Jianhua Fan; Rosie Kim; Xinyi Wang; Kathryn O'Brien; Yong Li; Yuting Kuang; Mei Chen; David T Woodley; Wei Li
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 2.  HSP90 inhibitors: current development and potential in cancer therapy.

Authors:  Katerina Sidera; Evangelia Patsavoudi
Journal:  Recent Pat Anticancer Drug Discov       Date:  2014-01       Impact factor: 4.169

3.  Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.

Authors:  Robert M Immormino; Yanlong Kang; Gabriela Chiosis; Daniel T Gewirth
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

4.  Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site.

Authors:  Csaba Soti; Akos Vermes; Timothy A J Haystead; Péter Csermely
Journal:  Eur J Biochem       Date:  2003-06

5.  Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

Authors:  Gabriela Chiosis; Brian Lucas; Alexander Shtil; Henri Huezo; Neal Rosen
Journal:  Bioorg Med Chem       Date:  2002-11       Impact factor: 3.641

6.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.

Authors:  Eloisi Caldas-Lopes; Leandro Cerchietti; James H Ahn; Cristina C Clement; Ana I Robles; Anna Rodina; Kamalika Moulick; Tony Taldone; Alexander Gozman; Yunke Guo; Nian Wu; Elisa de Stanchina; Julie White; Steven S Gross; Yuliang Ma; Lyuba Varticovski; Ari Melnick; Gabriela Chiosis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-05       Impact factor: 11.205

Review 7.  Evaluation of HIF-1 inhibitors as anticancer agents.

Authors:  Gregg L Semenza
Journal:  Drug Discov Today       Date:  2007-09-18       Impact factor: 7.851

8.  Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells.

Authors:  Suman Ghosh; Heather E Shinogle; Gaurav Garg; George A Vielhauer; Jeffrey M Holzbeierlein; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Chem Biol       Date:  2014-12-03       Impact factor: 5.100

9.  Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity.

Authors:  Krystal D Nolan; Jasmine Kaur; Jennifer S Isaacs
Journal:  Oncotarget       Date:  2017-03-21

10.  Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.

Authors:  Kristin Beebe; Mehdi Mollapour; Bradley Scroggins; Chrisostomos Prodromou; Wanping Xu; Mari Tokita; Tony Taldone; Lester Pullen; Bettina K Zierer; Min-Jung Lee; Jane Trepel; Johannes Buchner; Daniel Bolon; Gabriela Chiosis; Leonard Neckers
Journal:  Oncotarget       Date:  2013-07
View more
  28 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 2.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

3.  P53 supports endothelial barrier function via APE1/Ref1 suppression.

Authors:  Mohammad A Uddin; Mohammad S Akhter; Agnieszka Siejka; John D Catravas; Nektarios Barabutis
Journal:  Immunobiology       Date:  2019-04-18       Impact factor: 3.144

4.  Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective.

Authors:  Adrienne L Edkins; John T Price; A Graham Pockley; Gregory L Blatch
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-19       Impact factor: 6.237

5.  Hsp90 inhibitors suppress P53 phosphorylation in LPS - induced endothelial inflammation.

Authors:  Nektarios Barabutis; Mohammad A Uddin; John D Catravas
Journal:  Cytokine       Date:  2018-11-09       Impact factor: 3.861

6.  Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain.

Authors:  Vasantha Kumar Mv; Radwan Ebna Noor; Rachel E Davis; Zheng Zhang; Edvinas Sipavicius; Dimitra Keramisanou; Brian S J Blagg; Ioannis Gelis
Journal:  Medchemcomm       Date:  2018-07-02       Impact factor: 3.597

Review 7.  Structure-guided approaches to targeting stress responses in human fungal pathogens.

Authors:  Emmanuelle V LeBlanc; Elizabeth J Polvi; Amanda O Veri; Gilbert G Privé; Leah E Cowen
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

8.  RNA-binding proteins and heat-shock protein 90 are constituents of the cytoplasmic capping enzyme interactome.

Authors:  Jackson B Trotman; Bernice A Agana; Andrew J Giltmier; Vicki H Wysocki; Daniel R Schoenberg
Journal:  J Biol Chem       Date:  2018-08-30       Impact factor: 5.157

9.  Effects of Inhibitors on Hsp90's Conformational Dynamics, Cochaperone and Client Interactions.

Authors:  Sonja Schmid; Markus Götz; Thorsten Hugel
Journal:  Chemphyschem       Date:  2018-05-25       Impact factor: 3.102

10.  Exploring the Prominent and Concealed Inhibitory Features for Cytoplasmic Isoforms of Hsp90 Using QSAR Analysis.

Authors:  Magdi E A Zaki; Sami A Al-Hussain; Syed Nasir Abbas Bukhari; Vijay H Masand; Mithilesh M Rathore; Sumer D Thakur; Vaishali M Patil
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.